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The New York Stem Cell Foundation’s “Sixth Annual Translational Stem Cell Research Conference” convened on
October 11–12, 2011 at the Rockefeller University in New York City. Over 450 scientists, patient advocates, and stem
cell research supporters from 14 countries registered for the conference. In addition to poster and platform presen-
tations, the conference featured panels entitled “Road to the Clinic” and “The Future of Regenerative Medicine.”
Introduction
The New York StemCell Foundation’s (NYSCF) an-
nual translational stem cell conference opened with
two panels of experts discussing current progress in
translating stem cell research to accelerate cures for
the major diseases of our time. In the first panel
“Road to the Clinic,” moderated by Lee Rubin, di-
rector of translationalmedicine at theHarvard Stem
Cell Institute and NYSCF scientific advisor, lead-
ing experts from the pharmaceutical, biotechnol-
ogy, and healthcare industries were joined by repre-
sentatives from venture capital and grant-awarding
foundations to discuss how to transfer stem cell
research from the laboratory into safe and effec-
tive treatments. Panelists included Stephen Chang
(New York Stem Cell Foundation), Scott John-
son (Myelin Repair Foundation), Robert J. Palay
(Cellular Dynamics International), and William A.
Sahlman (Harvard Business School). The panel dis-
cussed the latest research developments and the
scientifically challenging path toward clinical tri-
als. The second panel, “The Future of Regenera-
tive Medicine,” composed of leading stem cell re-
searchers and policy makers, discussed from their
differing perspectives the regulatory challenges fac-
ing researchers on the road to the clinic. Moderator
and chief executive officer of the New York Stem
Cell Foundation Susan L. Solomon, and panelists
Mahendra S. Rao (NIH Intramural Center for Re-
generative Medicine), Craig B. Thompson (Memo-
rial Sloan-Kettering Cancer Center), Marc Tessier-
Lavigne (The Rockefeller University), and Irving
L. Weissman (Stanford University) examined the
changes in policy that will be needed to advance the
development, evaluation, and approval of emerging
stem cell treatments and regenerative medicine.
As in previous years, the second day of the confer-
ence convened an international panel of researchers
at the forefront of the stem cell field who presented
their work on diabetes, heart and muscles, cancer
and blood disease, neurodegeneration, and pro-
gramming/reprogramming.1,2 The panel included
a groundbreaking report on somatic cell nuclear
transfer (SCNT), recently published in Nature by
Dieter Egli at the NYSCF laboratory.
In addition to a keynote address by Irving
L. Weissman, who discussed the latest devel-
opments in cancer treatments using stem cells,
the inaugural recipient of the NYSCF–Robertson
Stem Cell Prize, Professor Peter J. Coffey (Univer-
sity College London, and the London Project to
doi: 10.1111/j.1749-6632.2012.06481.x
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Cure Blindness) presented his forthcoming clini-
cal trial using stem cells to treat age-related macular
degeneration.
NYSCF, in collaboration with Annals of New York
Academy of Sciences, is delighted to present this re-
port; compiled by young stem cell scientists, it sum-
marizes the excellent, groundbreaking progress in
stem cell research.
Diabetes
The opening speaker, Hans Snoeck (Mount Sinai
School of Medicine), discussed the importance of
using stem cells to generate thymus tissue. In vivo,
the thymus is the immune organ inwhichT cell pos-
itive and negative selection takes place. Thymus tis-
sue derived in vitro has potential therapeutic appli-
cations, such as enhancingT cell reconstitution after
allogeneic bone marrow transplantation. Human-
ized mouse models can be created by transplanting
thymus generated from human stem cells, which
are extremely valuable for studying human autoim-
mune diseases, including type 1 diabetes.3 Snoeck
showed that when using activin A, BMP4, and basic
fibroblast growth factor (bFGF), his group differen-
tiated human embryonic stem cells into anterior en-
doderm, fromwhich thymic tissue is derived. Subse-
quent treatmentwithNoggin and SB-431542directs
endoderm cells toward anterior foregut fate, with
more than 90%of the cells expressing SOX2.4 By ap-
plying knowledge- and screening-based approaches,
Snoeck’s group discovered combinations of various
factors, including Wnt3A, fibroblast growth factor
10 (FGF10), keratinocyte growth factor (KGF), and
sonic hedgehog (SHH), that could further specify
foregut endoderm cells to become lung bud or pha-
ryngeal endoderm cells. Notably, Snoeck pointed
out that Wnt3A is crucial to prepattern the cells
for lung development, and that retinoic acid in-
duces lung fate partly through suppression of TBX1,
a transcription factor necessary for pharyngeal
development.
Shuibing Chen (Weill Cornell Medical College;
Fig. 1) summarized previous and ongoing efforts
to generate pancreatic  cells from stem cells, in-
cluding hypothesis-driven approaches based on an-
imal models and in vitro studies that work well
for the early stages of differentiation, specifically
during the definitive endoderm and gut-tube endo-
derm stage.5 In order to efficiently direct the cells
into pancreatic progenitors and  cells, however,
she and her colleagues have been using discovery-
driven screen approaches to search for the optimal
conditions to facilitate this transition. After screen-
ing with chemical libraries, they identified a small
molecule, (–)-indolactam V, that can promote the
generation of pancreatic progenitors by activating
protein kinase C (PKC) signaling.6 Recently, Chen’s
group screened for growth factors and cell lines that
induce pancreatic progenitor and  cell generation
and showed that mouse pancreatic endothelial cells
and a human endothelial cell line (AKT-HBVEC)
significantly enhance the proliferation of pancreatic
progenitors in culture. Furthermore, Chen found
that cell–cell contact is not required and the effect
is mediated by factors that belong to the epidermal
growth factor (EGF) family. Currently, the insulin-
producing  cells derived in vitro are immature
 cells, which do not display great response to glu-
cose. Chen’s group is now seeking a cellular niche
that can accelerate the proliferation and/or matura-
tion of  cells.
The final talk in this session was given by Pedro
Herrera (University of Geneva) who introduced the
intriguing phenomenon of  cell to  cell transi-
tion. Herrera’s group has developed new transgenic
models allowing near-total  cell or  cell removal,
specifically in adult mice; these mouse models en-
able the study of pancreas regeneration after mas-
sive cell loss. Herrera and colleagues showed that six
months after  cell removal, new  cells were re-
generated. Around 20% of newly generated  cells
express both glucagon and insulin, hormones pro-
duced by  cells and  cells, respectively. Using cell-
tracing technology, Herrera and colleagues demon-
strated that some of the newly formed  cells were
derived from cells.7 In contrast, they also observed
thatwhenmostof cells are removed, the remaining
2% of the normal  cell mass is enough to main-
tain healthy and euglycemic mice.8 Taken together,
these studies suggest that future diabetic therapies
could involve regenerating  cells via reprogram-
ming adult  cells.
Cancer and blood disease
Shahin Rafii (Howard Hughes Institute and Weill
Cornell Medical College) opened this session and
described a recently identified instructive role of
pulmonary capillary endothelial cells (PCECs) in
supporting lung regeneration.9 Previous work from
the Rafii group established the novel concept that
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Figure 1. Shuibing Chen (Weill Cornell Medical College and NYSCF-Robertson investigator) presents her work on deriving
functional pancreatic endocrine cells from human pluripotent stem cells.
capillary endothelial cells (CECs) not only func-
tion as passive conduits to meet metabolic de-
mand, they also stimulate paracrine (angiocrine)
growth factors to induce and sustain organ regen-
eration.10–14 In bone marrow (BM)10–12 and liver,13
sinusoidal endothelial cells (SECs) constitute phe-
notypically and functionally distinct populations
of cells. After partial hepatectomy, liver SECs—via
angiocrine production of hepatocyte growth factor
and Wnt2 (a process defined as inductive angiogen-
esis)—stimulate hepatocyte proliferation.13 Subse-
quently, liver SECs undergo proliferative angiogene-
sis tomatch the increasing demand for blood supply
in the regenerating liver. Likewise, after chemother-
apy and irradiation, activated BM SECs induce
hematopoiesis by angiocrine generation of Notch
ligands and insulin-like growth factor binding pro-
teins (IGFBPs).10,12
To investigate the role of PCECs in support-
ing lung regeneration, Rafii’s group generated a
unilateral pneumonectomy (PNX) mouse model
by performing surgical resection of the left lung
lobe. Without perturbing the vascular integrity
of the remaining lobes, PNX induces significant
growth of mass, volume, and physiological respira-
tory capacity of the remaining lungs. This regener-
ation process is due to neoalveologenesis, a process
involving amplification of alveolar epithelial pro-
genitor cells and PCECs. The phenotypic and op-
erational markers of mouse PCECs were defined
as VE-cadherin+ VEGFR2+ FGFR1+ CD34+ ECs.
They further demonstrated that PNX, through ac-
tivation of VEGFR2 and FGFR1, induces PCECs of
the remaining lobes to produce the angiocrine ma-
trix metalloproteaseMMP14. In turn, MMP14 pro-
motes regenerative alveolarization by unmasking
cryptic EGF-like ligands that stimulate proliferation
of epithelial progenitor cells. These studies under-
score the instrumental role of endothelial-derived
angiocrine signals in instructing adult organ regen-
eration. Selective activation of CECs, or increas-
ing the generation of angiocrine factors in patients,
would promote organ regeneration, thereby offer-
ing therapeutic avenues for end-stage liver, lung, and
hematopoietic diseases.
The second speaker of the session was Viviane
Tabar (Memorial Sloan-Kettering Cancer Center),
whose laboratory focuses on understanding the al-
terations within the brain stem cell niche that are
responsible for glioblastoma tumors. Previously, it
was demonstrated that a subpopulation of CD133+
cancer stem cells are responsible for the initiation
of glioblastoma tumors.15 Tabar’s group discov-
ered that CD133+ cancer stem cells not only ini-
tiate the tumor but also generate new endothelial
cells necessary for tumor self-maintenance.16 The
newly generated cells presented a different geno-
type when compared with normal blood vessel
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Figure 2. Catriona Jamieson (University of California, SanDiego) discusses themolecular evolution of leukemia stem cells during
the session entitled “Cancer and Blood Disease.”
cells in the brain: the cells have an amplification
of the EGF receptor gene and the centromere of
chromosome 7, two typical mutations of different
glioblastomas variants.17 Tabar and colleagues iso-
lated CD133+ cells from human glioblastoma sam-
ples and cultured them in vitro to test their ability
to generate tumor vessels. Interestingly, they found
that after seven days in vitro, CD133+ cancer stem
cells differentiate into blood vessel cells expressing
CD105, CD31, and CD34, which are typical en-
dothelial markers in the brain. Tabar’s group con-
firmed this in vivo by inoculating NOD/SCID mice
with CD133+ GFP+ cells isolated from glioblastoma
tumors. Their results showed that gliobastomas that
developed in NOD/SCID mice were characterized
by GFP+ blood vessels cells, suggesting that the
CD133+ cancer stem cells were able to differenti-
ate in vivo into endothelial cells necessary for tumor
self-maintenance. Together, these data provide new
insights for thedevelopmentof novel drugs or thera-
pies for treating glioblastomas that aim at inhibiting
the endothelial transition of CD133+ cancer stem
cells.
The third speaker of the session was Catri-
ona Jamieson (University of California, San Diego;
Fig. 2). Her talk explored the molecular evolu-
tion of leukemia stem cells (LSCs) during progres-
sion of chronic myeloid leukemia (CML) from the
chronic phase (CP) to blastic phase (BP). Several
studies have shown that CML is characterized by
the Philadelphia (Ph) chromosome, which has a
BCR/ABL1 rearrangement with enhanced kinase
activity.18 Although it has been assumed that the
BCR/ABL1 mutation occurs first in hematopoi-
etic stem cells (HSCs) that are responsible for the
development of theCML-CPphase,19 little is known
about the molecular mechanisms that trigger the
disease to transition to the more severe CML-BP
phase. Using RNA sequencing and nanoproteomics
approaches, Jamieson identified splice variants and
point mutations that commonly occur in all CML
tumor samples processed. These candidate genes
are grouped into three classes: (1) genes involved in
LSC aberrant self-renewal (such as Jak2), (2) genes
involved in LSC dormancy (Shh), and (3) genes
that promote LSC survival (Bcl2). Using inhibitors
against these genes, Jamieson presented preliminary
in vitro results: (1) TG101348, a Jak2 inhibitor, when
combined with desatinib, a BCR/ABL1 inhibitor,
arrested stem cell self-renewal ability; (2) Shh in-
hibitors were able to reactivate the stem cell cycle
transition from G0 to G1; and (3) sabutoclax, a
pan-inhibitor of the Bcl2 family, induced apopto-
sis of LSCs, thus arresting the blast phase. Taken
together, these preliminary results support the pos-
sible use of these target genes for development of
novel therapeutics aimed at inhibiting CML-BP de-
velopment.
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Keynote address
Thefirst invitedkeynote speakerwas IrvingL.Weiss-
man (Stanford University; Fig. 3), whose work on
hematopoiesis has been essential for defining the
stages of development from hematopoietic stem
cells (HSC) to their mature progeny. Many years
of work on hematopoietic tissue, much of it led
byWeissman’s laboratory, has characterized pheno-
typically and genotypically nearly every step of dif-
ferentiation of stem cells to mature progeny. Some
of this basic science knowledge has been essen-
tial in understanding how normal hematopoietic
cells become leukemic cells. For example,Weissman
and colleagues have shown that despite preleukemic
progression (such as EML1/ETO translocation) in
HSCs, accumulationof further events in the progen-
itor compartment is responsible for the formation
of leukemic stem cells (LSC).20 Weissman’s group
identified the cell marker CD47, which is upregu-
lated in mouse and human acute myeloid leukemia
(AML) stem cells and functions as a “don’t eat me
signal.” Weissman’s group demonstrated that ex-
pression of CD47 on a human leukemia cell line
improves tumor engraftment in immunodeficient
mice due to evasion byCD47-expressing tumor cells
of phagocytosis.21 This suggests that cancer stem
cells can defeat programmed cell removal by upreg-
ulating CD47 on their surface, which has led the
way to a new anticancer treatment: blocking CD47
with an antibody so that phagocytosis can elimi-
nate tumor cells, for example, AML stem cells.22
Selective targeting of tumor cells by CD47 antibody
is explained by the simultaneous presence on tu-
mor cells, but not on most normal cells, of calreti-
culin, which acts as a prophagocytic signal.23 Fur-
thermore, the combination of CD47 antibody with
rituximab, a monoclonal antibody that engages Fc
receptors on NK cells and macrophages, has a syn-
ergistic action that results in total elimination of
human non-Hodgkin lymphomas in mice.24 Fur-
ther studies on bladder, ovarian, and breast cancers
suggest that different tumors use the same mecha-
nism to escape immunosurveillance and can there-
fore be attacked by anti-CD47 treatment. This is a
great example of translational research based on the
evolution from basic science to the development of
new drugs against human cancers.
Repairing our heart and muscles
The skeletal and cardiac muscle tissues constitute a
large portion of the human body and are character-
ized by a set of different conditions that affect their
Figure 3. Irving L. Weissman (Stanford University and NYSCF Medical Advisory Board Member), Marc Tessier-Lavigne (The
Rockefeller University and NYSCF Medical Advisory Board Member), Susan L. Solomon (CEO, New York Stem Cell Foundation),
Mahendra S. Rao (Center for Regenerative Medicine, National Institutes of Health, and NYSCFMedical Advisory BoardMember),
and Craig B. Thompson (Memorial Sloan Kettering Cancer Center and NYSCF Medical Advisory Board Member) gather after a
panel discussion entitled “The Future of Regenerative Medicine.”
20 Ann. N.Y. Acad. Sci. 1255 (2012) 16–29 c© 2012 New York Academy of Sciences.
Marshall et al. NYSCF: Sixth Annual Conference
functionality. The understanding of the molecular
mechanisms governing the development, regenera-
tion, and repair of these tissues is fundamental for
developing innovative therapeutic solutions for the
treatment of a large variety of medical conditions
associated with disability and death.
During her presentation Margaret Buckingham
(Institut Pasteur) addressed the role of satellite stem
cells in skeletal muscle regeneration, as well as the
function of Pax genes and downstream targets in
different stages of tissue development and regener-
ation. Satellite cells, quiescent cells found between
the basement membrane and the sarcolemma of in-
dividualmuscle fibers, undergoprofound transcrip-
tional changes upon activation. Microarray analy-
sis of in vivo quiescent and activated cells reveals
how satellite cells protect from oxidative damage,
maintain quiescence, and are primed for activation
when proper signals are provided.25 This finding
sheds light on the importance of extracellular ma-
trix degradation for satellite cell migration and acti-
vation and demonstrates that upregulation of pro-
teinases is crucial for optimal tissue regeneration
in vivo. Buckingham’s group has focused on the
expression of Pax3 and its regulation of the myo-
genic determination factor Myf5 during develop-
ment and regeneration. Genetic analysis and chro-
matin immunoprecipitation studies reveal that Pax3
specifically binds a conserved sequence upstream
of Dmrt2 and regulates its expression. During tis-
sue development, Dmrt2 regulates the early activa-
tion of the Myf5 gene (Myf5), which plays a central
role in the formation of the first skeletal muscle
in the somite.26 In contrast, Myf5 is already tran-
scribed in satellite stem cells of adult muscle be-
fore the onset of myogenesis, although translation
into a functional protein is repressed via binding
of microRNA-31 and subcellular sequestration of
the microRNA–RNA complex in ribonucleopro-
tein granules. Consistent with this expression of
microRNA-31, antagonists of microRNA-31 in an-
imal models of injury promoted tissue regenera-
tion and increased fiber size. Upon activation, this
post-transcriptional repression is released and cells
undergo myogenic differentiation.27 Buckingham
highlighted the importance of silencing and seques-
tering tissue-specific regulatory gene transcripts to
ensure rapid responses to tissue damage, and how
similar control mechanisms may be involved in the
regeneration of other somatic tissues.
Next, Deepak Srivastava (University of Cali-
fornia, San Francisco) discussed his group’s ef-
forts to develop novel therapeutic strategies for
human cardiac disorders based on known devel-
opmental pathways. By studying key molecular
events during heart development, Srivastava’s lab
has identified a cascade of transcription factors and
microRNAs that regulate early differentiationof car-
diac progenitors and, later, their expansion into ven-
tricular chambers.28–36 Many of these pathways can
be used to guide differentiation of pluripotent stem
cells into cardiac, endothelial, and smooth muscle
cells that may be useful for regenerative medicine.
One example of translating these observations into
regenerative approaches is the group’s recent success
in direct reprogramming of cultured mouse post-
natal cardiac fibroblasts (CFs) into cardiomyocyte-
like cells using a combination of three core devel-
opmental transcription factors, Gata4-Mef2C-Tbx5
(GMT).37 These induced cardiomyocytes (iCMs)
express cardiac-specific markers, have a global
gene expression profile similar to neonatal car-
diomyocytes, and exhibit spontaneous Ca2+ flux,
electrical activity, and contraction. Compared to
iPSC reprogramming, reprogramming of CFs to
iCMs with GMT occurs more rapidly (starting at
day 3) and with a higher efficiency, up to 20%.
Furthermore, Srivastava’s unpublished data con-
firm that this technique also works in vivo. Using
a Cre-mediated lineage tracing technique, his group
has demonstrated that resident CFs can be repro-
grammed into iCMs through retrovirus-mediated
GMTtransductionofmouseheart. Interestingly, the
in vivo reprogramming efficiency was greater than
that observed in vitro; and iCMs exhibited proper-
ties, such as connexin 43 (Cx43) localization, ultra-
structure under an electron microscope, action po-
tential, and contractility, that closely resemble the
native adult cardiomyocytes, suggesting a more
complete reprogramming than in vitro. Most im-
portantly, reprogrammed iCMs found in the scar
zone formed after myocardium infarction resulted
in improved cardiac function. Given that CFs nor-
mally compose over 50% of all the cells in the heart,
these findings raise the possibility of reprogram-
ming the vast pool of endogenous CFs into func-
tional cardiomyocytes for regenerative purposes.
Michael Rudnicki (Ottawa Health Research In-
stitute; Fig. 4) presented work on the identification
of signaling pathways that regulate the function of
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Figure 4. MichaelRudnicki (OttawaHealthResearchInstitute,
Canada) presents his latest work with molecular regulation of
muscle stem cell function.
satellite stem cells in adult skeletal muscle. Satel-
lite stem cells support growth, homeostasis, and
regenerationof skeletalmuscle tissue through asym-
metric (apical–basal) and symmetric (planar) divi-
sions.38 His laboratory has found that satellite cells
uniformly express the transcription factor Pax7.39
However, studies in mice have demonstrated that
10% of cells within the Pax7 population are neg-
ative for Myf5. Pax7+Myf5– cells were found to
give rise to Pax7+Myf5+ cells through asymmet-
ric division within the satellite cell niche, indi-
cating a positional control of cell fate. In agree-
ment with this, transplantation studies revealed
that the Pax7+Myf5+ cells are a subpopulation of
myogenic progenitors that preferentially differen-
tiate, whereas Pax7+Myf5– cells contribute to satel-
lite niche repopulation.40 The ability of Pax7+Myf5–
cells to expand the satellite pool suggests that
these cells may have therapeutic potential in treat-
ing a large variety of degenerative disorders af-
fecting the skeletal muscle system. Furthermore,
Rudnicki described the mechanism through which
Pax7 activity is regulated upon asymmetric cell
division, resulting in Myf5 transcription. Tandem
affinity purification and mass spectroscopy anal-
ysis led to the identification of a set of cofactors
interacting with Pax7, including the Wdr5-Ash2L-
MLL2 histone methyltransferase complex, which
directs chromatinmodification and allows the tran-
scription of myogenic determination genes.41 Simi-
lar studies have led to identification of additional
Pax7 interacting proteins, such as protein argi-
nine N-methyltransferase-4 (CARM1/PRMT4).
CARM1 binds Pax7 and regulates its function,
through methylation of N-terminal arginines,
which is necessary for the recruitment of the Wdr5-
Ash2L-MLL2 complex. Mutation of the methyla-
tion sites in the Pax7 sequence reduces the ability
of Pax7 to upregulate Myf5 transcription, indicat-
ing a direct control of myogenic specification by
CARM1 in the satellite compartment. Rudnicki also
presented new findings demonstrating the common
embryonic origin of brown fat and skeletal mus-
cle. Isolated Pax7+Myf5+ satellite cells were found
to differentiate toward the adipogenic lineage when
appropriately stimulated. The transcription factor
PDRM16 was found to control the bidirectional
fate switch between skeletal myoblasts and brown
fat cells. Knockdown of PDRM16 in brown fat pre-
cursor results in increased expression of myogenic
genes, whereas ectopic expression of PDRM16 in
myoblasts induces brown fat differentiation. Fur-
thermore, immunopurification studies followed by
mass spectroscopy demonstrate that PDRM16 in-
teracts with PPAR- ,42 recognized as a master tran-
scriptional regulator of adipogenesis.43 These data
indicate a direct control of PDRM16 on brown fat
differentiation.
Neurodegeneration and spinal cord injury
Steven Goldman (University of Rochester Medi-
cal Center), the first speaker of the session enti-
tled “Neurodegeneration and Spinal Cord Injury,”
presented recent work on a new strategy to iso-
late human oligodendocyte progenitor cells (OPCs)
from fetal human brain.44 Following previously
published data from his lab, in which OPCs were
isolated by FACS based on the expression of the
cell surface ganglioside marker A2B5, Goldman’s
group identified that OPCs can be further enriched
by isolating cells expressing the receptor CD140a
(PDGFRa), a subpopulation of the A2B5+ cells.45
CD140a+ cells from human fetal brain, depleted
of neuronal- and astrocytic-specific markers, are
able to migrate and myelinate neuronal axons when
transplanted into the hypomyelinated mouse brain.
Myelination was faster and more efficient than that
observed after transplantation of A2B5+ cells that
were not further enriched for CD140a expression.
This finding holds true when human CD140a+ cells
are transplanted in chemically induced demyeli-
nating rat brains and when OPCs are produced
from human iPS cells, though with variable effi-
ciency rates. Finally, Goldman presented interest-
ing unpublished data from experiments with the
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shiverer mouse model following transplantation of
CD140a+ human OPCs into the mouse brains. The
cells gave rise to myelinating oligodendrocytes and
astrocytes, and the brainswere found tobe chimeric,
with >70% of the glial cells being of human origin
(8months posttransplantation), suggesting that hu-
mandonor cells outpace host-derived cells. Further-
more, the transplanted cells retained a human phe-
notype and function with high synaptic potentia-
tion. Interestingly, Pavlovian-based behavioral tests
show that the chimeric mice are better at learning
by association and can be conditioned to fear faster
than their wild-type counterparts, a sign that these
micemight be “smarter.” In addition to allowing the
study of basic biological interactions of human glial
cells, this strategy provides a unique mouse model
in which to study diseases of the central nervous sys-
tem, including human-specific infectious diseases.
In the second talk of the session, Paul Tesar (Case
WesternReserveUniversity)presented recentlypub-
lished work on the differentiation of mouse epiblast
stem cells (EpiSCs) to OPCs.46 Tesar and his group
are attempting toproducepurepopulationsofOPCs
by directed differentiation, using the signals that
normally play important roles during normal devel-
opment of oligodendrocytes, and to identify the re-
quired developmental transitions to produce func-
tional OPCs. In the first stage, pluripotent EpiSCs
are specified to the neuroectodermal lineage and
cells are organized into typical neural rosette struc-
tures by blocking the activin-nodal and BMP signal-
ing pathways for four days. In the second stage, the
neuroectodermal-like cells are patterned to region-
specific neural precursor cells by addition of retinoic
acid and SHH for one day. In the final stage, produc-
tion of OPCs results from platelet-derived growth
factor (PDGF) and FGF signaling after an addi-
tional five days. This ten-day differentiation pro-
tocol results in a population of highly enriched cells
expressing OPC-specific markers that display the
typical bipolar morphology of in vivo counterparts.
Such mouse EpiSC-derived OPCs can be expanded
for at least eight passages—results consistent across
four independent EpiSC lines. After a further four
days, the OPCs differentiate to highly specific ma-
ture oligodendrocytes (lacking any neuronal or as-
trocytic markers) that express basic myelin protein.
The functionality of theseOPCswas tested by inject-
ing them into forebrain slices from the hypomyeli-
nated shiverer mouse. In this context, the cells
produced oligodendrocytes that migrated and
myelinated neuronal axons in the host mouse brain
tissue. Tesar reported that similar experiments are
under way to find analogous methodologies that
will robustly produce OPCs from human iPS cells.
Finally, Tesar presented data (submitted) involving
direct conversion of fibroblasts to OPCs, with a 10–
15% efficiency; the OPCs could expand, differenti-
ate to mature oligodendrocytes, and myelinate sec-
tions of shiverer mouse brain.
Clive Svendsen (Cedars-Sinai Regenerative
Medicine Institute) presented two approaches to
treating Huntingon’s disease (HD) and other neu-
rodegenerative disorders. The first part of his talk
summarized his lab’s work over the previous 14
years using fetal brain tissue transplant approaches
as a therapeutic intervention for HD and Parkin-
son’s disease (PD) models.47,48 This method in-
cludes isolation of human progenitors from the fetal
cortex and then passage of the cells by a “chopping
method” to insure cell–cell contact. After 20 pas-
sages, these progenitors can differentiate, at a high
percentage, to astrocytes. Such astrocyte progenti-
tors, injected into animal models, produce human
astrocytes that take 120 days to mature. The thera-
peutic potential of these cells can be amplified using
ex vivo gene therapy enabling the cells to produce
the neuroprotectant glial cell–derived neurotrophic
factor. This combination is effective in modulating
the deleterious effects observed in the N171–82Q
mouse model of HD1. Svendsen described attempts
to move this approach to clinical application for a
variety of neurologic disorders, including HD, ALS,
macula degeneration, and stroke. The second part
of Svenden’s talk described the progress of the iPSC
Stem Cell Consortium for Huntington’s disease,
which is a collaboration between investigators from
multiple research institutions, including Svendsen’s,
to generate and characterize HD patient-specific
iPSCs. This unpublished work, funded by an NIH
Grand Opportunities Grant, provides an opportu-
nity for analysis of the HD iPSCs by groups with
different expertise, as well as independent valida-
tion of experimental results by different laborato-
ries. iPSCs have been generated from patients with
different levels of CAG repeats in the Huntington
gene. The number of CAG repeats dictates whether
a person will develop HD and positively correlates
with age of onset.49 Various labs within the consor-
tium have demonstrated numerous disease-related
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phenotypes for neurons generated from multiple
clones of higher CAG repeat iPSCs, including delays
in neuronal maturation, adhesion properties, ATP
metabolism, and cell death in response to stresses
such as acute pulses of glutamate and BDNF with-
drawal. Sensitivity to glutamate is also associated
with decreased ability to reset calcium homeosta-
sis, which may explain why HD neurons are more
sensitive to excitotoxic insults.
NYSCF-Robertson Prize lecture
During the NYSCF–Robertson Prize lecture, Peter
J. Coffey (University College London; Fig. 5) pre-
sented an overview of the work he has done with the
London Project to Cure Blindness to find a treat-
ment for age-related macular degeneration (AMD).
AMD affects roughly 14 million older adults in the
United States and in Europe. Currently, dry AMD,
which affects 90% of the clinical population, has no
known therapeutic treatment. Wet AMD, which af-
fects 10% of the clinical population, can be treated
with anti-VEGF therapy, but this therapy is expen-
sive and time consuming, as patients must receive
monthly injections of drugs into the eye.
In wet AMD, blood vessels, which perfuse blood
into the retina, protrude through a weakened
Bruch’s membrane, the membrane dividing the
choroid and the retinal pigment epithelial (RPE)
cell layer.50 The protrusion of these blood vessels
into the RPE cell layer compromises its function
and cuts off the nutrition and structural support it
provides for the photoreceptors, eventually leading
to detachment of the macula and vision loss.51 In
order to treat wet AMD, Coffey and colleagues have
developed amacular translocation surgery in which
the macula is reconstructed via its rotation. Macu-
lar translocation resulted in 25% of patients gaining
three lines of acuity up to three years after surgery.52
However, this surgery is very complex and time con-
suming, and the cost per patient is exceedingly high.
Therefore,Coffey and colleagues attemptedmacular
translocation with 360◦ retinotomy and autologous
RPE–choroid patch graft, which has dramatically
reduced costs as well as potential surgical complica-
tions, such as trauma to the photoreceptors them-
selves. However, RPE–choroid patch grafts were
found to be inferior to macular translocation alone,
partially because exogenous RPE grafts lacked suffi-
cientmetabolic support and the graftmembranedid
not allow sufficient attachment of the grated cells to
the Bruch’s membrane.53 To address the problem of
exogenous transplantation rejection, Coffey’s group
was first able to develop RPE cells generated from
hESCs and successfully transplant these cells into
the RCS rat model with inherited retinal degenera-
tion. His group showed that photoreceptors could
Figure 5. Peter J. Coffey (University College London, the London Project to Cure Blindness, and recipient of the Inaugural
NYSCF-Robertson Prize in Stem Cell Research) delivers a special keynote address on his use of human ESCs to cure age-related
macular degeneration.
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be rescued using both electrophysiological and be-
havioral tests, such as pattern discrimination and
head tracking after implantation of hESC-derived
RPE cells.54,55 Indeed, grafts of RPE cells derived
from iPS cells into RCS rats induce the short-term
maintenance of photoreceptors and significantly in-
crease visual acuity.56 Coffey reported that experi-
ments using choroid patch grafts from RPE-hESCs
in pig retina result in the proliferation of functional
photoreceptors with normal autofluorescence, in-
dicating that the insertion of choroid patch grafts
from RPE-hESCs into human eyes shows signifi-
cant promise in the treatment of wet AMD. Phase
I/II clinical trials based on this research are proposed
for 2012.
Programming and reprogramming
Dieter Egli (New York Stem Cell Foundation; Fig.
6), the first speaker of the session entitled “Program-
ming and Reprogramming,” reported on two recent
publications aimed at generating patient-specific
stem cells through the use of somatic cell nuclear
transfer (SCNT). Egli first highlighted growing con-
cerns about iPS cells, stressing the need for contin-
ued work in SCNT.57–59 However, many labs have
failed to fulfill the potential of SCNT, thus posing
the question of whether these failures are because of
the preliminary nature of the studies, or because of
an intrinsic issue with the human egg that prevents
reprogramming.
Beginningwith his experience atHarvardUniver-
sity, Egli highlighted the issues of recruiting oocyte
donors when only “altruistic donors” can be en-
rolled.60 After moving to the New York Stem Cell
Foundation, Egli’s study continued in collaboration
with Columbia University Medical Center’s Center
for Women’s Reproductive Care (CWRC), where,
to date, 16 donors have participated. Initial experi-
ments corroborated previous findings but also sug-
gested that developmental failure was due to tran-
scriptional dysfunction. Using microarray analysis,
the expression profile of such failures closely resem-
bled oocytes treated with transcriptional inhibitor
aminitin, raising the following questions: (1) Is ar-
tificial activation of the oocyte causing this arrest?
This was not the case, as parthenogenetic blastocysts
could be made. (2) Is oocyte manipulation causing
this arrest? This was answered no by demonstrating
that if the genome was removed and replaced into
the same oocyte, parthenogenetic blastocysts could
still form. (3) Is the somatic cell genome interfer-
ing with early development, or is it the removal of
the oocyte genome? To answer this, a somatic cell
(GFP labeled) was fused to an oocyte with an intact
oocyte genome. Following activation, development
to the blastocyst stage demonstrated GFP activation
and, hence, that the somatic cell genome had partic-
ipated in blastocyst development. Stem cells derived
from the blastocysts developed into all three germ
layers and expressed markers typical of stem cells.
Figure 6. Dieter Egli (the New York Stem Cell Foundation) shares his groundbreaking work on reprogramming after nuclear
transfer in the session entitled “Programming and Reprogramming.”
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However, these stem cells were karyotypically ab-
normal, with a triploid genome. To eliminate the
issue of timing, the oocyte genome was removed
at the first interphase, which led to developmen-
tal arrest. Sequencing analysis of both gDNA and
cDNA was undertaken with an allelic ratio of ∼0.6
found in both, suggesting that the somatic genome
was as active as the oocyte genome. Analysis of gene
expression profiles of the stem cells showed that
there was no preferential expression of either fi-
broblast or stem cell genes, suggesting that no “so-
matic memory” was present.61 This work suggests
that the oocyte can reprogram the somatic genome,
and further work is now under way to identify what
causes developmental arrest following removal of
the oocyte genome.
Alex Meissner (Harvard University; Fig. 7) be-
gan his talk by referencing the same issues that
Egli raised concerning iPS cells. While acknowledg-
ing that critical investigation is warranted, Meissner
pointed out that there is also a wide range in vari-
ation among ES cells lines. These variations were
shown by methylation mapping, gene expression
profiling, and use of a quantitative differentiation
assay. Furthermore, while some iPS cell lines do not
cluster with ES lines in these analyses, many do,
suggesting that they are as useful as many ES lines.62
Meissner went on to discuss DNA methylation dy-
namics and how to further our understanding of
where and when DNA methylation is used as a reg-
ulatorymechanism. He described unpublished data
that highlights the critical role of DNA methyla-
tion during development. Zygotes from fertilized
mouse oocytes were collected at multiple times dur-
ingdevelopment. Itwas initially found that although
therewere fewdifferences in globalmethylation pat-
terns between E7.5 and adult tissue, analysis of the
oocyte itself revealed a globally lower level ofmethy-
lation than that in sperm. Following fertilization, a
continuous shift in demethylation (of the paternal
genome) is seen until E6.5 at implantation. Further-
more, the inner cell mass (ICM) of the blastocyst
appears to differ greatly from that of the somatic
genome in which classically low CpG dense areas
are highly methylated. It was also found that for a
number of genes, includingDnmt1, separate mater-
nal and somaticmethylationpatterns exist.Until the
eight-cell stage of development, the somatic Dnmt1
CpG island is highly methylated before switching
to a demethylated state, with the opposite being
true for the maternal version. From unpublished,
ongoing, collaborative work with Egli, the initial
analysis of mouse nuclear transfer zygotes appears
to show that nuclear transfer blastocysts show com-
parable global demethylation to that seen in zygotes.
It appears, however, that similar to sperm, theoocyte
is capable of removing some methylation from pre-
viously highly methylated areas, although a num-
ber of regions remain as methylated as in the so-
matic cell. Therefore, remodeling by the oocyte does
take place; however, not all regions are remodeled
equally.
Kevin Eggan (New York Stem Cell Foundation
and Harvard University) ended the programming
Figure 7. Alex Meissner (Harvard University) discusses his progress in epigenetic reprogramming.
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and reprogramming session by discussing his re-
cently published work describing the direct con-
version of mouse and human fibroblasts into in-
duced motor neurons (iMNs) by a process referred
to as transdifferentiation.63 Thepurpose of this study
was to generate amyotrophic lateral sclerosis (ALS)
disease-specific motor neurons by transdifferentia-
tion,which subsequently could be compared to sim-
ilarly derived control motor neurons. Eggan, who
pioneered the first ALS-specific iPS cells that could
make disease-specific motor neurons,64 suggested
that iMNs, owing to their significantly faster gen-
eration time, could provide a quicker preview of
disease-specific phenotypes than iPS approaches.
Eggan’s group first attempted to generate iMNs
by virally overexpressing eight transcription factors
alone, or in combination, known to be important
for either the motor neuron differentiation process
or in thematuremotor neuron itself. This approach
was unsuccessful in generating iMNs from fibrob-
lasts obtained from HB9:GFP mice (which pro-
duce GFP-fluorescing motor neurons). However,
when Eggan’s group combined this strategywith the
three transcription factors used by Marius Wernig’s
group to create more general neurons from fibrob-
lasts (iNs),65 they successfully generated iMNs. This
could be reduced to a six or seven transcription fac-
tor cocktail, and could also be used to create iMNs
from human fibroblasts. Similar to iNs,66 the trans-
differentiation process to iMNs does not appear
to involve a neural progenitor intermediate. iMNs
were shown to resemble bona fide motor neurons
by a variety of criteria, including gene expression
studies, electrophysiological properties, formation
of cholingeric synapses with muscle cells generated
from the C2C12 cell line, and implantation into
the developing chick spinal cord with subsequent
appropriate axonal migration to peripheral targets.
Eggan finished his talk by showing preliminary un-
published data suggesting that human iMNs pre-
pared from ALS patients with genetic forms of the
disease demonstrate increased electrical excitability
compared to control iMNs, which could predispose
the former to increased sensitivity to excitotoxic
insults.
Conclusion
NYSCF’s sixth annual meeting convened leaders in
stem cell research, both senior and innovative young
scientists, providing attendees with novel scientific
presentations that focused on a wide variety of dis-
eases and techniques. The speakers, including two
scientists from NYSCF’s inaugural class of NYSCF-
Robertson investigators, gave conference partici-
pants a first-hand look at unpublished and recently
published pioneering research. The “Seventh An-
nual Translational Stem Cell Research Conference”
will take place on October 10–11, 2012.
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